Overview

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II study is studying how well giving AZD0530 works in treating patients with extensive-stage small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Saracatinib